Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Science. 2021 Feb 19;371(6531):803-810. doi: 10.1126/science.abf5972.
Although bespoke, sequence-specific proteases have the potential to advance biotechnology and medicine, generation of proteases with tailor-made cleavage specificities remains a major challenge. We developed a phage-assisted protease evolution system with simultaneous positive and negative selection and applied it to three botulinum neurotoxin (BoNT) light-chain proteases. We evolved BoNT/X protease into separate variants that preferentially cleave vesicle-associated membrane protein 4 (VAMP4) and Ykt6, evolved BoNT/F protease to selectively cleave the non-native substrate VAMP7, and evolved BoNT/E protease to cleave phosphatase and tensin homolog (PTEN) but not any natural BoNT protease substrate in neurons. The evolved proteases display large changes in specificity (218- to >11,000,000-fold) and can retain their ability to form holotoxins that self-deliver into primary neurons. These findings establish a versatile platform for reprogramming proteases to selectively cleave new targets of therapeutic interest.
尽管定制的、序列特异性的蛋白酶具有推动生物技术和医学发展的潜力,但生成具有定制切割特异性的蛋白酶仍然是一个主要挑战。我们开发了一种带有正、负选择的噬菌体辅助蛋白酶进化系统,并将其应用于三种肉毒神经毒素(BoNT)轻链蛋白酶。我们将 BoNT/X 蛋白酶进化为分别优先切割囊泡相关膜蛋白 4(VAMP4)和 Ykt6 的变体,将 BoNT/F 蛋白酶进化为选择性切割非天然底物 VAMP7,将 BoNT/E 蛋白酶进化为切割磷酸酶和张力蛋白同源物(PTEN),而不是神经元中的任何天然 BoNT 蛋白酶底物。进化后的蛋白酶在特异性上发生了巨大变化(218 至 >11,000,000 倍),并且能够保留其形成自传递到原代神经元的完整毒素的能力。这些发现为重新编程蛋白酶以选择性切割治疗相关新靶标建立了一个多功能平台。